IRIS Accounts Production v24.3.0.553 10000693 Board of Directors 1.9.23 31.8.24 31.8.24 false true false false true false Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh100006932023-08-31100006932024-08-31100006932023-09-012024-08-31100006932022-08-31100006932022-09-012023-08-31100006932023-08-3110000693ns15:EnglandWales2023-09-012024-08-3110000693ns14:PoundSterling2023-09-012024-08-3110000693ns10:Director12023-09-012024-08-3110000693ns10:PrivateLimitedCompanyLtd2023-09-012024-08-3110000693ns10:SmallEntities2023-09-012024-08-3110000693ns10:AuditExempt-NoAccountantsReport2023-09-012024-08-3110000693ns10:SmallCompaniesRegimeForDirectorsReport2023-09-012024-08-3110000693ns10:SmallCompaniesRegimeForAccounts2023-09-012024-08-3110000693ns10:FullAccounts2023-09-012024-08-3110000693ns10:OrdinaryShareClass12023-09-012024-08-3110000693ns10:Director22023-09-012024-08-3110000693ns10:Director32023-09-012024-08-3110000693ns10:CompanySecretary12023-09-012024-08-3110000693ns10:RegisteredOffice2023-09-012024-08-3110000693ns5:CurrentFinancialInstruments2024-08-3110000693ns5:CurrentFinancialInstruments2023-08-3110000693ns5:Non-currentFinancialInstruments2024-08-3110000693ns5:Non-currentFinancialInstruments2023-08-3110000693ns5:ShareCapital2024-08-3110000693ns5:ShareCapital2023-08-3110000693ns5:RetainedEarningsAccumulatedLosses2024-08-3110000693ns5:RetainedEarningsAccumulatedLosses2023-08-3110000693ns5:PlantMachinery2023-09-012024-08-3110000693ns5:PlantMachinery2024-08-3110000693ns5:DisposalsRepaymentsInvestments2024-08-3110000693ns5:CostValuation2024-08-3110000693ns5:WithinOneYearns5:CurrentFinancialInstruments2024-08-3110000693ns5:WithinOneYearns5:CurrentFinancialInstruments2023-08-3110000693ns5:Non-currentFinancialInstrumentsns5:AfterOneYear2024-08-3110000693ns5:Non-currentFinancialInstrumentsns5:AfterOneYear2023-08-3110000693ns5:Non-currentFinancialInstrumentsns5:BetweenTwoFiveYears2024-08-3110000693ns5:Non-currentFinancialInstrumentsns5:BetweenTwoFiveYears2023-08-3110000693ns5:BetweenOneFiveYearsns5:HirePurchaseContracts2024-08-3110000693ns5:BetweenOneFiveYearsns5:HirePurchaseContracts2023-08-3110000693ns10:OrdinaryShareClass12024-08-31
REGISTERED NUMBER: 10000693 (England and Wales)













Unaudited Financial Statements

For The Year Ended 31 August 2024

for

JAJ PHARMA LIMITED

JAJ PHARMA LIMITED (REGISTERED NUMBER: 10000693)






Contents of the Financial Statements
For The Year Ended 31 August 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


JAJ PHARMA LIMITED

Company Information
For The Year Ended 31 August 2024







DIRECTORS: J Pradyuman Jani
Mrs M Jaykumar Jani
S P Soni





SECRETARY: J Pradyuman Jani





REGISTERED OFFICE: 79 College Road
Harrow
Middlesex
HA1 1BD





REGISTERED NUMBER: 10000693 (England and Wales)





ACCOUNTANTS: Ayman Tyler Associates
Accountants & Tax Advisers
79 College Road
Harrow
Middlesex
HA1 1BD

JAJ PHARMA LIMITED (REGISTERED NUMBER: 10000693)

Balance Sheet
31 August 2024

31.8.24 31.8.23
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 81,396 -
Investments 5 - 54
81,396 54

CURRENT ASSETS
Debtors 6 16,369,533 956,000
Cash at bank 5,675,195 -
22,044,728 956,000
CREDITORS
Amounts falling due within one year 7 240,206 307,266
NET CURRENT ASSETS 21,804,522 648,734
TOTAL ASSETS LESS CURRENT
LIABILITIES

21,885,918

648,788

CREDITORS
Amounts falling due after more than one year 8 85,524 33,505
NET ASSETS 21,800,394 615,283

CAPITAL AND RESERVES
Called up share capital 11 100 100
Retained earnings 21,800,294 615,183
SHAREHOLDERS' FUNDS 21,800,394 615,283

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 August 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 August 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

JAJ PHARMA LIMITED (REGISTERED NUMBER: 10000693)

Balance Sheet - continued
31 August 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 27 September 2024 and were signed on its behalf by:





J Pradyuman Jani - Director


JAJ PHARMA LIMITED (REGISTERED NUMBER: 10000693)

Notes to the Financial Statements
For The Year Ended 31 August 2024

1. STATUTORY INFORMATION

JAJ Pharma Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery etc - 25% on cost

Investments in associates
Investments in associate undertakings are recognised at cost.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 3 (2023 - 2 ) .

JAJ PHARMA LIMITED (REGISTERED NUMBER: 10000693)

Notes to the Financial Statements - continued
For The Year Ended 31 August 2024

4. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
£   
COST
Additions 108,529
At 31 August 2024 108,529
DEPRECIATION
Charge for year 27,133
At 31 August 2024 27,133
NET BOOK VALUE
At 31 August 2024 81,396

5. FIXED ASSET INVESTMENTS
Interest
in
associate
£   
COST
At 1 September 2023 54
Disposals (54 )
At 31 August 2024 -
NET BOOK VALUE
At 31 August 2024 -
At 31 August 2023 54

On 6th November 2023,the following disposals took place:
18 Ordinary shares in Liqmeds Worldwide Limited were sold for an upfront consideration of £5,242,317.82 and a further ascertainable deferred consideration of £15,534,400.00 receivable on an earn out basis over 3 years from date of completion.
36 Ordinary shares in Medsolutions (Europe) Limited were sold for an upfront consideration of £204,098.89 and a further ascertainable deferred consideration of £604,800.00 receivable on an earn out basis over 3 years from date of completion.

JAJ PHARMA LIMITED (REGISTERED NUMBER: 10000693)

Notes to the Financial Statements - continued
For The Year Ended 31 August 2024

6. DEBTORS
31.8.24 31.8.23
£    £   
Amounts falling due within one year:
Trade debtors - 360,000
Other debtors 230,333 596,000
230,333 956,000

Amounts falling due after more than one year:
Other debtors 16,139,200 -

Aggregate amounts 16,369,533 956,000

Other debtors balance due within 1 year includes £230,273 loaned to Sapphire Investments Group Ltd.

Other Debtors balance of amounts due more than 1year refers to an amount of £16,139,200 of ascertainable deferred consideration to be received on an earn out basis over 3 years..

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.8.24 31.8.23
£    £   
Taxation and social security 5,585 70,162
Other creditors 234,621 237,104
240,206 307,266

8. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR
31.8.24 31.8.23
£    £   
Bank loans (see note 9) - 33,505
Hire purchase contracts (see note 10) 85,524 -
85,524 33,505

9. LOANS

An analysis of the maturity of loans is given below:

31.8.24 31.8.23
£    £   
Amounts falling due between two and five years:
Bank loans - 2-5 years - 33,505

JAJ PHARMA LIMITED (REGISTERED NUMBER: 10000693)

Notes to the Financial Statements - continued
For The Year Ended 31 August 2024

9. LOANS - continued

The company received a government backed bounce back loan for £50,000 on 2nd October 2020 and repaid the loan in full during the year.

10. LEASING AGREEMENTS

Minimum lease payments under hire purchase fall due as follows:

31.8.24 31.8.23
£    £   
Net obligations repayable:
Between one and five years 85,524 -

On 19th April 2024 the company entered into a 3 year Hire Purchase agreement, with the option to purchase the asset for £47,675.00 at the end of term.

11. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 31.8.24 31.8.23
value: £    £   
100 Ordinary 1 100 100

The shareholdings in the company are as follows;

Mansi Jaykumar Jani 80 Ordinary Shares of £1 each
Sanket Pankajkumar Soni 10 Ordinary Shares of £1 each
Krupa Dave 10 Ordinary Shares of £1 each